Copyright
©The Author(s) 2023.
World J Crit Care Med. Mar 9, 2023; 12(2): 71-88
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Table 1 Studies showing efficacy of different devices for cytokine and endotoxin removal
Ref. | Study type | Population | Modality | Intervention | Outcomes |
Tapia et al[28], 2012 | Prospective cohort study | 31 severe septic shock patients | HVHF, Cytokine removal | HVHF – single short term – 6 h at 40 mL/kg/h | 25/31 responded to HVHF. Decrease in NE dose and improvement in hemodynamic, metabolic and respiratory parameters were significantly improved by 4 h |
Joannes-Boyau et al[29], 2013 | Prospective, randomized, open multicentre trial | 137 septic shock patients (AKI < 24 h) | HVHF, Cytokine removal | HVHF – 70 mL/kg/h vs standard volume hemofiltration at 35 mL/kg/h | No difference in hemodynamic stability, severity scores, 28-d mortality, length of stay and vasopressor free days |
Livigni et al[30], 2014 | Prospective, randomized, multicentre parallel group trial | 192 septic shock patients | CPFA, Cytokine & endotoxin removal | Conventional therapy (n = 93) vs CPFA (n = 91) | Decreased mortality in patients receiving high dose of CPFA. No difference in length of ICU stay and new organ failures in 30 d |
Atan et al[31], 2018 | Randomized controlled trial | 76 critically ill patients with AKI | CVVH -HCOCytokine removal | CVVH-HCO (n = 38) – cut off point 100 kDa vs CVVH -Std (n = 38) – cut off point 30 kDa | No difference was observed in mortality, duration of hemofiltration, norepinephrine dose, serum albumin levels and filter life |
Dellinger et al[32], 2018 | Randomized, multicentre trial | 449 septic shock patients | Polymyxin B hemoperfusion; Endotoxin removal | Polymyxin B hemoperfusion + Standard therapy vs Sham hemoperfusion + Standard therapy | No significant difference in 28 d mortality in overall population or in patients with MODS score of > 9 |
Kaçar et al[33], 2020 | Prospective observational study | 23 septic shock patients with AKI | HA 330 Cytokine removal | HA 330 hemoperfusion + CVVH for 2 h once daily for 3 d | Increase in pH was observed after 1st application HA330 hemoperfusion; CRP and PCT levels decreased significantly after 2nd application |
Table 2 Multiple logistic regression analysis to predict 30 d mortality
Ref. | Study design | Population | Intervention | Outcomes |
Friesecke et al[62], 2017 | Prospective, single center study | 20 septic shock patients | CytoSorb hemoperfusion | Norepinephrinedose reduced after 6 and 12 h; Improved lactate clearance; SOFA scores unchanged; Shock reversal achieved in 65% of patients; 28-d survival – 45% |
Kogelmann et al[63], 2017 | Case series | 26 septic shock patients | CytoSorb+CVVHD | Rapid hemodynamic stabilization; Reduction in Vasopressor dose by 67%; Decrease in blood lactate by 26.4%; Shock reversal in 38.5% patients; Decreased mortality than predicted by APACHE II; No adverse events reported |
Friesecke et al[52], 2017 | International registry | 135 septic shock patients | CytoSorb hemoperfusion | Reduced observed mortality of 65% than predicted by APACHE II of 78%; Marked reduction in IL6 levels; No significant reduction in SOFA scores; Safe and well tolerated without any adverse events |
Brouwer et al[59], 2019 | Retrospective, investigator-initiated study | 116 septic shock patients | CytoSorb +CRRT | In CytoSorb group, the mean predicted mortality rate was 74.5%, while 28 d mortality rate was 47.8%; In CRRT group, the mean predicted mortality rate was 67.9%, while 28-d mortality was 51.0%; CytoSorb group was associated with a reduced 28-d mortality in comparison to CRRT (53% vs 72.3%) |
CRRT alone | ||||
Brouwer et al[60], 2021 | Long term follows up | 116 septic shock patients | CytoSorb +CRRT | CytoSorb was significantly associated with long term outcome compared to CRRT |
Retrospective cohort study | CRRT alone | |||
Mehta et al[53], 2020 | Retrospective, observational study | 40 septic shock patients | CytoSorb hemoperfusion (Survivor group vs non survivor group) | Improvement in MAP (62.82 ± 9.73mmHg); Reduction in vasopressor dose; Reduction IL-6 levels (87%) and TNF levels (24%); Decrease in SOFA scores by 16.2% |
Paul et al[68], 2021 | Prospective, real time, observational multicentre study | 45 septic shock patients | CytoSorb+ Standard therapy | 26 patients survived post therapy; Reduction in vasopressor dose (NE- 51.4%, Epinephrine – 69.4% and Vasopressin -13.9%); 52.3% reduction in IL-6 levels; Reduction in APACHE II and SOFA scores, 20.1 ± 2.47 and 9.04 ± 3.00 respectively |
(Survivor vs non survivor group) | ||||
Akil et al[69], 2020 | 20 patients with pneumogenic sepsis and ARDS | CytoSorb + Combined high flow veno-venous ECMO (CytoSorb group); ECMO therapy alone (Control group) | The 30-d mortality rate was 0% in CytoSorb group, whereas 57% was observed in control group; Significant reduction in procalcitonin and C-reactive levels were observed in CytoSorb group in comparison to control group | |
Rugg et al[61], 2020 | Retrospective single center study | 42 septic shock patients compared to 42 matched controls | Cytosorb +RRT | Catecholamines requirements decreased to 0.26 µg/kg/min within 24 h of therapy with CytoSorb; In hospital mortality was significantly lower in CytoSorb group as compared to controls (35.7% vs 61.9%); Risk factors in CytoSorb group were high lactate levels and low thrombocyte counts proior to therapy. Lactate value of 7.5 mmol/L, predicted mortality with high specificicty (88.9%) |
Table 3 Studies determining efficacy of CytoSorb in coronavirus disease 2019 infection
Ref. | Study type | Population | Intervention | Outcomes |
Alharthy et al[70], 2020 | Retrospective case series | 50 COVID-19 patients with AKI, ARDS, Sepsis and hyperinflammation | CytoSorb + CRRT [Survivors (n = 35) vs non survivors (n = 15)] | Decreased SOFA score, lactate levels, ferritin, D-dimers, CRP and IL-6 levels in th survivor group after 2 ± 1 sessions of CRRT + CytoSorb |
Mehta et al[64], 2021 | Case series | 3 critically ill COVID-19 patients | CytoSorb hemoperfusion other prescribed medications (tocilizumab, antivirals, hydroxychloroquine, azithromycin) | Significant improvement in biochemical parameters and clinical outcomes post CytoSorb therapy; Reduction in CRP levels by 91.5%, 97.4% and 55.75%, respectively; Improvement in MAP by 18%, 23% and 17% by 7th day post therapy |
Nassiri et al[71], 2021 | Retrospective case series | 26 COVID-19 patients with ARDS | CytoSorb hemadsorption therapy | 21 patients survived; Significant decrease in NE requirement; PCT, CRP and ferritin reduced post therapy; Significant improvement in SOFA scores; Therapy was well tolerated |
Paisey et al[72], 2021 | Retrospective case series | 15 severely ill COVID-19 patients | CytoSorb hemadsorption therapy | Adjunctive treatment with CytoSorb lead to reduction in ferritin, CRP, PCT and lactate levels |
Song et al[73], 2021 | Multicenter observational study | 52 ICU COVID -19 patients on ECMO | ECMO + CytoSorb hemadsorption therapy | ICU mortality was 17.3% on day 30, 26.9% on day 90, and 30.8% at final follow up of 143 d; Lower baseline D-Dimer levels were observed among survivors (2.3 ± 2.5 vs 19.8 ± 32.2 µg/mL) compared to non survivors; Borderline association observed between baseline D-Dimer levels and mortality with a 32% increase in risk of death per 1 µg/mL increase |
Table 4 Multiple logistic regression analysis to predict 30 d mortality
Feature | CytoSorb 300[84,85,86] | Jafron HA-series (80, 130, 180, 230, 280, 330, 380)[87] | Biosky MG-Series[88] |
Manufacturer | CytoSorbents™ Inc, United States | Jafron Biomedical Co., Ltd. No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China | Biosun Medical Technology Co. Ltd, China |
IFU version | October 1, 2021[87] | 11-Sep-19 | 1-Aug-18 |
Adsorbent | Crosslinked Divinylbenzene | Neutral Macroporous Resin | Medical Neutral Macroporous Synthetic Resin |
Coating | Polyvinylpyrollidone | Collodion | No data |
Adsorbent Surface | > 45000 m2 | 100000m2 | No data |
Storage fluid | Isotonic saline | Water for injection | Sterile water |
Use time/cartridge | 24 h, Can be administered up to 7 consecutive days | Depending on mode of operation: Hemoperfusion 100-250 mL/ min; Dialysis < 320 ml/ min with use upto 4 h; CRRT 150-250 mL/min with use upto 12 h; CPB up to 700 mL/ min with use upto 2.5 h | 120-180 min, Not suggested to use more than 3 times within 24 h |
Blood flow | 100-700 mL/min, Recommended > 150 mL/min | 100-700 mL/min | 100-400 mL/min; Highest rate is 250 mL/min |
Pmax | 760 mmHg | 750 mmHg | 750 mmHg |
Mode of operation covered | Hemoperfusion, Intermittent hemodialysis, CRRT, Cardiopulmonary bypass (CPB) ECMO | Hemoperfusion; Hemodialysis; CRRT; CPB | Hemoperfusion; Hemodialysis; CRRT; CPB only as comment in anticoagulation, not in setup |
Shelf life | 3 yr | 2 yr | 2 yr |
Safety report status | As of 2021: > 162000 treatments distributed without confirmed serious device related events | No data | No data |
Table 5 Studies determing oxiris efficacy for removal of endotoxins and cytokines
Ref. | Study type | Population | Intervention | Outcomes |
Shum et al[98], 2013 | Prospective case series with historical controls | 6 patients with septic AKI | oXiris + CVVH | Significant reduction in SOFA scores by 37% after 48 h of therapy |
Ugurov et al[96], 2020 | Single centre case series | 15 COVID -19 patients | oXiris hemofilter | Early initiation of oXiris was associated with stable or reducing levels of IL-6,8,10 and TNFα |
Zhang et al[49], 2021 | Case series | 5 COVID-19 patients | CRRT followed by oXiris hemofilter therapy | Reduced levels of cytokines, haemodynamic stabilization and improvement of organ function was observed with oXiris. |
Rosalia et al[100], 2020 | Prospective cohort study | 44 COVID 19 cases | CVVH + oXiris | Reduction in CRP, ferritin, fibrinogen and other inflammatory mediators were observed |
- Citation: Mehta Y, Paul R, Ansari AS, Banerjee T, Gunaydin S, Nassiri AA, Pappalardo F, Premužić V, Sathe P, Singh V, Vela ER. Extracorporeal blood purification strategies in sepsis and septic shock: An insight into recent advancements. World J Crit Care Med 2023; 12(2): 71-88
- URL: https://www.wjgnet.com/2220-3141/full/v12/i2/71.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v12.i2.71